China Regulator Approves IND Application of Oramed Oral Insulin

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. (‘HTIT’), has reached the significant regulatory milestone of approval of an investigational new drug application (‘IND’) for two doses of its oral insulin (ORMD-0801). The approval of the IND by the Center For Drug Evaluation of the China National Medical Products Administration (‘NMPA’, formerly the CFDA) of the oral insulin paves the way for the start of clinical trials in China.

‘We are pleased that the Chinese regulatory authorities have approved the IND, as it sets a clear path forward for approval of oral insulin in China, bringing oral insulin closer to becoming a reality in the Chinese market,’ stated Oramed CEO Nadav Kidron.

https://www.marketscreener.com/ORAMED-PHARMACEUTICALS-I-12562638/news/Oramed-Pharmaceuticals-Chinese-Regulatory-Authority-Approves-IND-Application-of-Oramed-s-Oral-Insu-28241047/